In HF treatment aimed at improving prognosis, quadruple therapy, which includes angiotensin-converting enzyme inhibitors (ACE-Is)/angiotensin II type 1a receptor blockers (ARBs)/angiotensin receptor neprilysin inhibitors (ARNIs), β-blockers (BBs), mineralocorticoid antagonists (MRAs), and sodium glucose cotransporter-2 inhibitors (SGLT2is), has been recommended for HF with reduced ejection fraction (EF) (HFrEF) [6,7]. This evidence concerns the gene ACE and hydrops fetalis.